Clonidine

證據等級: L5

預測適應症: 10 個

Clonidine: From Hypertension to Tourette Syndrome

One-Sentence Summary

Clonidine is a central α2-adrenergic agonist with long-established clinical use for hypertension, and in its extended-release form (Kapvay), for ADHD treatment in children and adolescents. The TxGNN model’s highest-evidence actionable prediction is Tourette Syndrome, backed by 2 directly relevant Phase 4 clinical trials, a 2024 multicenter double-blind RCT, 2 network meta-analyses / systematic reviews (2022–2023), and a total of 19 publications supporting this repurposing direction.

Note on ranking: TxGNN assigns its highest numerical score to “faciodigitogenital syndrome” (rank #1, 99.9999%) — however, this carries no supporting evidence (L5, Hold) and is assessed as a knowledge-graph false positive. Tourette Syndrome (TxGNN rank #5) is the highest-evidence actionable prediction and is the focus of this report.

Quick Overview

Item	Content
Original Indication	Hypertension; ADHD (extended-release, FDA-approved as Kapvay)
Predicted New Indication	Tourette Syndrome
TxGNN Prediction Score	99.98%
Evidence Level	L2
US Market Status	Data not retrieved (0 records in system; Catapres® / Kapvay® are known US approvals)
Number of NDAs	0 (system returned 0 results — data gap)
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data was not available in this Evidence Pack. Based on information embedded in the repurposing rationale and established pharmacological knowledge, clonidine acts as a central α2A-adrenergic receptor agonist. By stimulating presynaptic α2 receptors in the locus coeruleus and prefrontal cortex, it suppresses norepinephrine release, reduces sympathetic outflow, and reinforces inhibitory control within frontal-subcortical circuits — the same circuitry implicated in impulse dysregulation and tic generation.

Tourette Syndrome (TS) is a neurodevelopmental disorder characterized by involuntary motor and phonic tics arising from dopaminergic and noradrenergic imbalance within the striato-thalamo-cortical loop. Clonidine’s reduction of locus coeruleus firing frequency directly targets the noradrenergic arm of this pathophysiology, dampening the hyperactivation signals that propagate through the basal ganglia and manifest as tics. A 2025 rat-model study (PMID 40392363) further demonstrated that clonidine attenuates neuroinflammation in TS — with elevated IL-2 in the basal ganglia confirmed in postmortem TS tissue — providing a mechanistic rationale beyond pure neurotransmitter modulation.

The clinical evidence for this repurposing direction is mature. Cohen et al. reported in 1979 (Lancet) that small doses of clonidine improved tic symptoms in children unresponsive to haloperidol — marking the earliest recognition of noradrenergic modulation as a TS treatment strategy. Four decades of subsequent clinical research culminated in the 2022 updated European Clinical Guidelines for TS, which formally recommend clonidine as a pharmacotherapy option, and a 2024 multicenter double-blind placebo-controlled RCT confirming efficacy of the clonidine adhesive patch formulation. A 2023 Lancet Child & Adolescent Health network meta-analysis further positions clonidine within the full comparative landscape of TS pharmacotherapies.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00370838	Phase 4	Completed	12	15-week double-blind crossover trial comparing clonidine vs levetiracetam for tic suppression in children with TS; clonidine functions as the established active comparator, confirming its standard-of-care status for tic suppression
NCT00152750	Phase 4	Unknown	32	Pharmacological intervention with clonidine for daytime aggression in children with TS + comorbid ADHD; proposed mechanism is improvement of nighttime sleep quality as a behavioral mediator

Literature Evidence

PMID	Year	Type	Journal	Key Findings
39258554	2024	RCT	Clinical Neuropharmacology	Multicenter randomized double-blind placebo-controlled trial confirming efficacy of clonidine adhesive patch in Tourette Syndrome
36528030	2023	Network Meta-analysis	Lancet Child & Adolescent Health	Comparative efficacy, tolerability, and acceptability of all pharmacological interventions for TS in children, adolescents, and young adults; positions clonidine in the evidence hierarchy
34757514	2022	Clinical Guidelines	European Child & Adolescent Psychiatry	Updated European Society for the Study of Tourette Syndrome guidelines formally recommending clonidine for TS pharmacotherapy, incorporating the latest meta-analysis and RCT data
31061209	2019	Systematic Review	Neurology	Comprehensive systematic review of tic treatment efficacy and risks in TS and chronic tic disorders, including clonidine
34286606	2021	Systematic Review	Journal of Psychopharmacology	Quality-of-evidence review for TS pharmacological treatments in children and adults
38695046	2024	Clinical Study	Psychiatry Investigation	Efficacy and safety of clonidine adhesive patch in TS patients with comorbid ADHD — dual-indication relevance
27132945	2016	Systematic Review	J Child Psychology & Psychiatry	Practitioner-focused systematic review of TS treatments for children and young people
40392363	2025	Animal Study	J Neuroimmune Pharmacology	Clonidine ameliorates neuroinflammation in rat TS model; α2-agonist anti-inflammatory effects corroborate mechanistic hypothesis alongside adrenergic modulation
24210663	2014	Clinical Study	Psychiatry Research	Clonidine in TS and sensorimotor gating — pharmacodynamic characterization study
89558	1979	Clinical Study	Lancet	Seminal report: small-dose clonidine improves TS in children unresponsive to haloperidol; first demonstration of noradrenergic mechanism in TS treatment

US Market Information

No US license records were retrieved for Clonidine in this Evidence Pack (0 authorizations returned). This is a data retrieval gap — clonidine is known to have established US market presence under the brand names Catapres® (hypertension) and Kapvay® (extended-release, ADHD in children 6–17 years). A manual query to the FDA Orange Book or DailyMed is recommended to obtain current NDA numbers, formulations, and full approved indication text.

Safety Considerations

Safety-specific data (key warnings, contraindications, drug-drug interactions) was not retrievable for this Evidence Pack. Based on safety signals referenced within the clinical literature reviewed:

Cardiovascular monitoring: Hypotension, bradycardia, and QTc prolongation are highlighted in the TS clinical literature as cardiovascular risks, particularly relevant in the pediatric population.

For comprehensive safety and drug interaction information, please refer to the official US prescribing information (Catapres® / Kapvay® label).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Clonidine’s efficacy in Tourette Syndrome is supported by more than four decades of clinical experience, a 2024 multicenter double-blind RCT, and formal endorsement in the 2022 European clinical guidelines. Its α2-adrenergic mechanism directly addresses the noradrenergic component of TS pathophysiology, making this one of the better-grounded repurposing predictions in this Evidence Pack. The main constraints are the US regulatory data gap in the current system and the absence of safety/contraindication data.

To proceed, the following is needed:

Manually retrieve full prescribing information from the US FDA (Catapres®/Kapvay® labels) or European equivalents to complete safety, contraindication, and drug-drug interaction analysis
Confirm current US NDA status and formulations via FDA Orange Book query
Define a cardiovascular safety monitoring protocol for TS patients: baseline and follow-up ECG (QTc), blood pressure, and heart rate assessments — especially for pediatric use
Evaluate the clonidine adhesive patch formulation (supported by the 2024 RCT) as a potential preferred route for TS, and assess local market availability
Conduct a regulatory feasibility assessment if filing for a TS indication is under consideration
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.